Last reviewed · How we verify
NCT06738511
Validation of a Molecular Signature for Early Detection of Colorectal Cancer
NA trial testing blood sampling in Colorectal Cancer Screening in 3,421 participants. Completed in 1 September 2021.
1 September 2021
Quick facts
| Lead sponsor | ADVANCED MARKER DISCOVERY S.L. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | screening |
| Enrollment | 3,421 |
| Start date | 28 May 2018 |
| Primary completion | 1 September 2021 |
| Estimated completion | 1 September 2021 |
| Sites | 2 locations across Germany, Poland |
Drugs / interventions tested
- blood sampling — full drug profile →
- stool sampling — full drug profile →
- colonoscopy
Conditions studied
- Colorectal Cancer Screening — all drugs for Colorectal Cancer Screening →
- Advanced Adenomas (AA) — all drugs for Advanced Adenomas (AA) →
Sponsor
ADVANCED MARKER DISCOVERY S.L.
Who can join
Adults 50 to 75, any sex, with Colorectal Cancer Screening or Advanced Adenomas (AA). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this Multicentre and international prospective study is to validate a molecular signature using plasma samples in average-risk population for colorectal cancer who undergo colonoscopy in a screening setting. The main question it aims to answer is: Does molecular signature in plasma sample have higher diagnostic accuracy than FIT for early detection of colorectal cancer? Participants who already have a colonoscopy as part of their regular medical care for colorectal cancer screening will provide a stool sample and a plasma sample.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Clinical Applications of Liquid Biopsy in Colorectal Cancer: A Focus on Registered Clinical Trials.
Garcia-Pelaez J, Yáñez Y, Aupí M, Lázaro M, et al · · 2026 · PMID 42194957 · DOI 10.3390/genes17050500
Verify or expand the search:
- PubMed search for NCT06738511
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of blood sampling
Trials testing the same drug.
- NCT07467109 — A Study to Evaluate the Safety and Efficacy of Intracranial Venous Blood Sampling for Liquid Biopsy in the Diagnosis of · not yet recruiting
- NCT07347613 — Long-term Follow-up of Diabetic Patients From the GLUTADIAB Study · not yet recruiting
- NCT07472387 — Impact of Androgen Signaling on the Composition of the Immune Microenvironment in Glioblastomas · NA · not yet recruiting
- NCT07477769 — Lymphocyte Phenotype of Autosomal Recessive Congenital Ichthyoses Mutated NIPAL4 (Nipal4-nEDD) · not yet recruiting
- NCT07236177 — B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosi · EARLY_PHASE1 · recruiting
Other recruiting trials for Colorectal Cancer Screening
Currently open trials in the same condition.
- NCT06757192 — CRC Screening in Unscreened Individuals 45-54 · recruiting
- NCT06763432 — Positive Fit to Colonoscopy: Closing the Gap · recruiting
- NCT06821009 — Effectiveness of a Cloud-based Digital Health Navigation Program for Colorectal Cancer Screening · NA · recruiting
- NCT06666556 — Bowel Preparation in Colonoscopy: Lactulose Vs Polyethyleneglycol, Randomized Double-blind Comparative Clinical Trial, M · Phase 4 · recruiting
- NCT07224750 — A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer · recruiting
Other ADVANCED MARKER DISCOVERY S.L. trials
Trials by the same sponsor.
- NCT06889883 — Development and Validation of a Blood Test for Early Diagnosis of Colorectal Cancer · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06738511 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by ADVANCED MARKER DISCOVERY S.L.
- Last refreshed: 17 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06738511.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing